Editorial: Assessing risk for cardiovascular disease in patients with human immunodeficiency virus: Why it matters

Circulation

Volumn 121, Issue 5, 2010, Pages 620-622

  Sax, Paul E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CYSTATIN C; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 6; TENOFOVIR;

ACUTE HEART INFARCTION; ARTERIAL WALL THICKNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CIGARETTE SMOKING; DISEASE ASSOCIATION; EDITORIAL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFLAMMATION; KIDNEY DISEASE; KIDNEY FUNCTION; MORTALITY; NEPHROTOXICITY; ONSET AGE; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SOCIAL STATUS; VIRUS REPLICATION; CHEMICALLY INDUCED DISORDER; NOTE; RISK FACTOR;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; HIV; HIV INFECTIONS; HUMANS; RISK FACTORS;

EID: 76649098868     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0b013e3181d2c863     Document Type: Editorial

References (23)

1. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, Vaeth M, Obel N. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146:87-95.
2. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, Pellegrin JL, Katlama C, Dabis F. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr. 2007;46:72-77.
3. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11-19.
4. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, Huebner RE, Janoff EN, Justice AC, Kuritzkes D, Nayfield SG, Plaeger SF, Schmader KE, Ashworth JR, Campanelli C, Clayton CP, Rada B, Woolard NF, High KP. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis. 2008;47:542-553.
5. Gill VS, Lima VD, Zhang W, Wynhoven B, Yip B, Hogg RS, Montaner JS, Harrigan PR. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis. 2010;50:98-105.
6. Gross J. AIDS patients face downside of living longer. New York Times, January 6 2008. Available at http://www.nytimes.com/2008/01/06/health/ 06HIV.html. Accessed January 20, 2010.
7. France D. Another kind of AIDS crisis. New York Magazine, November 1, 2009. Available at http://nymag.com/health/features/61740/. Accessed January 20, 2010.
8. Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, Tien PC, Shlipak MG, Sidney S, Polak JF, O'Leary D, Bacchetti P, Kronmal RA. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009;23:1841-1849.
9. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007; 92:2506-2512.
10. Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, Mack WJ, Cohen MH, Jacobson L, Gange SJ. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007;45: 1074-1081.
11. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsley LA. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978-2982.
12. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiebaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
13. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fatkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
14. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD; INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
15. Neuhaus J, Jacobs D, the INSIGHT SMART, MESA and CARDIA Study Groups. Markers of inflammation, coagulation, and renal function in HIV-infected adults in the Strategies for Management of ART Study and in 2 large population-based studies, coronary artery risk development in young adults and multi-ethnic study of atherosclerosis. [Abstract 740.]
16. 16th Conference on Retroviruses and Opportunistic Infections. February 8-11, 2009; Montreal, Canada.
17. Shikuma C, Zheng E, Ribaudo H. 96-week effects of suppressive efa-virenz containing ART, abacavir, and sex on high-sensitivity C-reactive protein: ACTG A5095 [Abstract 736]. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. February 8-11, 2009; Montreal, Canada.
18. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dubé MP, Lipshultz SE, Hsue PY, Squires K, Schambelan M, Wilson PW, Yarasheski KE, Hadigan CM, Stein JH, Eckel RH. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008;118:198-210.
19. Choi AI, Yongmei L, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. The association between kidney function and albuminuria with cardioavascular events in HIV-infected persons. Circulation. 2010;121: 651-658.
20. Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, Oleske JM, Currier JS, Gallant JE; HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:651-681.
21. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, Fields TA, Svetkey LP, Flanagan KH, Klotman PE, Winston JA. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004;66:1145-1152.
22. D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;37:1417-1426.
23. Apolonio EG, Hoover DR, He Y, Saah AJ, Lyter DW, Detels R, Kaslow RA, Phair JP. Prognostic factors in human immunodeficiency virus-positive patients with a CD4+ lymphocyte count <50/microL. J Infect Dis. 1995;171:829-836